ラットモデルの世界市場予測（～2021）：モデル種類別（非近交系、近交系、ノックアウト）、技術別、治療分野別、サービス別、ケア製品別、需要先別...市場調査レポートについてご紹介

1 Introduction (Page No. – 20)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 24)
2.1 Research Methodology
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.1.1 Key Data From Secondary Sources
2.2.2 Primary Research
2.2.2.1 Key Data From Primary Sources
2.2.2.2 Key Insights From Primary Sources
2.2.2.3 Key Industry Insights
2.3 Market Size Estimation Methodology
2.4 Market Forecast Methodology
2.5 Market Data Validation and Triangulation
2.6 Assumptions for the Study

3 Executive Summary (Page No. – 35)
3.1 Introduction
3.2 Conclusion

4 Premium Insights (Page No. – 43)
4.1 Rat Model Market Overview
4.2 Regional Analysis: Global Rat Care Product Market, By Type
4.3 Global Rat Model Market, By Therapeutic Area, 2016 & 2021
4.4 Regional Snapshot of the Global Rat Model Market

5 Market Overview (Page No. – 46)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Advancements in Gene Editing Tools Set to Augment the Demand for Rat Models
5.2.1.2 Advantages Offered By Rats Over Mice
5.2.1.3 Continuous Support in the Form of Investments and Grants
5.2.1.4 Increased Demand for Personalized Humanized Rat Models Due to Growing Consumption of Personalized Medicines
5.2.1.5 Increase in R&D Activities Carried Out By Pharmaceutical and Biotechnology Companies
5.2.2 Restraints
5.2.2.1 Regulations & Laws Formulated for Ethical Use of Animals
5.2.2.1.1 the Animal Welfare Act (AWA)
5.2.2.1.2 Public Health Service Policy (PHS) on Humane Care and Use of Laboratory Animals
5.2.2.2 Increased Benefits Offered By Cryopreservation
5.2.3 Opportunities
5.2.3.1 Increased Production of Monoclonal Antibodies
5.2.3.2 Rising Demand of Humanized Rat Models
5.2.4 Challenges
5.2.4.1 Advancements in Zebrafish Model Development
5.2.4.2 Development of Methods Alternative to Animal Testing

6 Clinical Trials & Research Studies Assessment (Page No. – 56)
6.1 Introduction
6.2 Clinical Trials
6.3 Research Studies

7 Global Rat Model Market, By Model Type (Page No. – 65)
7.1 Introduction
7.2 Outbred Rats
7.3 Inbred Rats
7.4 Knockout/Genetically Engineered Rats
7.5 Hybrid/Congenic Rats
7.6 Conditioned/Surgically Modified Rats
7.7 Immunodeficient Rats

8 Global Rat Model Market, By Service (Page No. – 74)
8.1 Introduction
8.2 Breeding
8.3 Cryopreservation
8.4 Quarantine
8.5 Rederivation
8.6 Model In-Licensing
8.7 Genetic Testing
8.8 Others
8.8.1 Surgical Services
8.8.2 Line Rescue Services
8.8.3 In Vivo Pharmacology Services

9 Global Rat Model Market, By Technology (Page No. – 85)
9.1 Introduction
9.2 Crispr
9.3 Microinjection
9.4 Embryonic Stem Cell Injection
9.5 Nuclear Transfer
9.6 Other Technologies

10 Global Rat Model Market, By Therapeutic Area (Page No. – 94)
10.1 Introduction
10.2 Toxicology
10.3 Oncology
10.3.1 New Product Launches for Oncology Research
10.3.2 Continuous Grants/Funds to Support Cancer Research Studies
10.4 Immunology and Inflammation
10.5 Neurology
10.6 Diabetes
10.7 Others

11 Global Rat Model Market, By End User (Page No. – 106)
11.1 Introduction
11.2 Pharmaceutical & Biotechnology Companies
11.3 Academic & Research Institutions
11.4 Contract Research Organizations (CRO)

12 Global Rat Model Market, By Care Product (Page No. – 112)
12.1 Introduction
12.2 Cages
12.3 Feed
12.4 Bedding
12.5 Other Care Products

13 Global Rat Model Market, By Region (Page No. – 119)
13.1 Introduction
13.2 North America
13.2.1 U.S.
13.2.1.1 Growing Biomedical Research in the U.S.
13.2.1.2 Preclinical Activities By Cros and Pharmaceutical R&D
13.2.1.3 Continued and Responsible Use of Animals Ensured By Animal Care Organizations
13.2.1.4 Development of Biosimilars Product Boosting the Demand for Preclinical Services
13.2.1.5 Monoclonal Antibody Production to Augment the Use of Rat Models
13.2.1.6 Partnership Between Cros and Pharmaceutical Companies
13.2.2 Canada
13.2.2.1 Growing Stem Cell Research Activities in Canada
13.2.2.2 Government Support for Development of Protein Drugs is Expected to Drive the Market
13.3 Europe
13.3.1 Germany
13.3.1.1 Launch of Pro-Test Deutschland
13.3.1.2 Flourishing Biotechnology Industry
13.3.2 U.K.
13.3.2.1 Investors Demand Strong Statistics for Animal Studies in the U.K.
13.3.2.2 Increase in Cell Therapy Preclinical Research
13.3.3 France
13.3.3.1 Funding for Rare Disease Projects in France
13.3.4 Russia
13.3.4.1 Growing Biomedical Industry in Russia
13.3.5 Rest of Europe
13.3.5.1 Growth in Biotech and Pharma Sector of Italy
13.3.5.2 Growing Investments in Research By Sweden & Denmark
13.3.5.3 Focus on Rare Disease Research Projects
13.3.5.4 Growth in Biosimilars Market to Lead to Increased Preclinical Activities
13.4 Asia-Pacific
13.4.1 China
13.4.1.1 International Alliances for R&D Activities in China
13.4.1.2 Initiatives to Reduce Longer Approval Times
13.4.1.3 Intellectual Property (Ip) Breaches, A Challenge for the China Market
13.4.1.4 Mandatory Animal Testing for All Pharmaceutical Drugs and Cosmetics in China
13.4.1.5 Increasing Investments From Government and Private Sectors in China’s Life Sciences Sector
13.4.2 Japan
13.4.2.1 Growth in Biomedical and Medical Research in Japan
13.4.2.2 Research in Regenerative Medicine
13.4.2.3 Focus on Cancer Research and Treatment
13.4.3 India
13.4.3.1 Growth of the Pharmaceutical Industry in India
13.4.3.2 Development of Bio-Clusters to Boost India’s Biotechnology
13.4.3.3 Growing Presence of Global Players
13.4.3.4 Shift of Outsourcing Preclinical Activities From India to European Nations
13.4.3.5 Weak Intellectual Property Environment in India
13.4.3.6 Limited Infrastructural Facilities in India, A Major Hindrance for Growth of the Rat Model Market
13.4.4 Rest of Asia-Pacific
13.4.4.1 Ongoing Biomedical Research Activities in Australia to Strengthen the Market
13.4.4.2 Growth in Translational and Biomedical Research in Singapore
13.4.4.3 Increase in Animal Research in Malaysia
13.4.4.4 Government Support for Strong Academic and Commercial R&D Activities in Taiwan
13.4.4.5 Rising Pharmaceutical and Biotechnology R&D Activities in Korea
13.5 Rest of the World
13.5.1 Pharmaceutical, Biotechnology, and Research Industries in Brazil to Drive Market Growth
13.5.2 Favorable Business Environment for Pharmaceutical and Biotechnology Industries in Saudi Arabia and the UAE
13.5.3 Increasing Investments in Mexico

14 Competitive Landscape (Page No. – 194)
14.1 Overview
14.2 Market Share Analysis
14.2.1 Introduction
14.2.2 Charles River Laboratories International, Inc. (U.S.)
14.2.3 Envigo (U.K.)
14.2.4 Taconic Biosciences, Inc. (U.S.)
14.3 Competitive Situation and Trends
14.4 Agreements, Collaborations, and Partnerships
14.5 Acquisitions
14.6 Expansions
14.7 New Product Launches
14.8 Other Strategies

15 Company Profiles (Page No. – 206)
(Overview, Products and Services, Financials, Strategy & Development)*
15.1 Introduction
15.2 Charles River Laboratories International, Inc.
15.3 Taconic Biosciences, Inc.
15.4 Envigo
15.5 Laboratory Corporation of America Holdings
15.6 Janvier Labs
15.7 Genoway S.A.
15.8 Biomere
15.9 Transposagen Biopharmaceuticals, Inc.
15.10 Horizon Discovery Group PLC
15.11 Transviragen, Inc.

*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.

16 Appendix (Page No. – 237)
16.1 Discussion Guide
16.2 Other Developments
16.2.1 Charles River Laboratories International, Inc.
16.2.2 Taconic Biosciences, Inc.
16.2.3 Envigo
16.2.4 Laboratory Corporation of America Holdings
16.2.5 Genoway S.A.
16.2.6 Horizon Discovery Group PLC
16.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
16.4 Introducing RT: Real-Time Market Intelligence
16.5 Available Customizations
16.6 Related Reports
16.7 Author Details